ModernMedicine Resource Center More Topics

DME Resource Center

Sustained-release corticosteroid implant improves, slows progression of diabetic retinopathySustained intraocular delivery of fluocinolone acetonide (FAc) using the FAc 0.19 mg intravitreal implant (Iluvien, Alimera Sciences) improves and slows progression of diabetic retinopathy (DR), according to findings of post-hoc analyses of data from the pivotal Fluocinolone Acetonide for Diabetic Macular Edema (FAME) trials.
Novel anti-VEGF-A agent shows promise for prolonged DME activityAbicipar pegol (Allergan/Molecular Partners) met its primary and key secondary endpoints and demonstrated an acceptable overall safety profile in a phase II trial investigating use of the novel anti-VEGF-A agent for treatment of diabetic macular edema (DME).
New biomarker may predict treatment response in DMEResearchers have identified a new biomarker they believe can be used as a predictor of vision change in patients with diabetic macular edema, either during the natural history of the disease or after undergoing anti-VEGF therapy. The biomarker is disorganization of the retinal inner layers, or DRIL.
New study affirms promise of anti-integrin drug for DME
New study affirms promise of anti-integrin drug for DMEA new class of ophthalmic drug continues to show promise for treating patients with diabetic macular edema (DME).
Future of DME resting on new mechanisms of actionWhen it comes to finding new treatments for diabetic macular edema (DME), there is no shortage of promising targets, said Peter A. Campochiaro, MD. He presented an overview of future compounds with various mechanisms of action that may change how clinicians treat DME.
Time for a paradigm shift in the treatment of DMEWell tolerated and effective, anti-VEGF therapy is the current gold standard to treat DME. However, one treatment simply does not fit all and VEGF may just be one piece of a much larger puzzle. The fact that some DME patients have a limited response to anti-VEGF therapy is representative of this concept; we are discovering that there are additional inflammatory mediators that may be crucial components to the DME picture.
Selecting the right DME patients for long-term steroidal implantsAn increasing number of treatment options have given patients facing diabetic macular edema (DME) new hope in the face of this chronic, progressive, and blinding disease. Experience and time have shown us there is not a one-size-fits-all solution for patients with DME. To get the results we want, we need to screen our patients and match them with the treatment protocol best suited to their needs.
Long-term efficacy for DME with fewer injections? Yes, please!As a physician passionate about treating and helping patients with retinal disease, I continuously seek out and study new treatment modalities. It can be a very scary time for patients when faced with retinal conditions, such as macular degeneration, retinal detachments, and diabetic macular edema (DME).
Case 1: 58-year-old patient with moderately severe DMERishi Singh, MD, explains a case with a patient with moderately severe DME.
Case 2: Same patient with more severe DME and history of cardiovascular eventsHear about the case, view the slides, and vote on your responses.